The estimated Net Worth of Uri Yablonka is at least $46.5 Thousand dollars as of 23 August 2017. Mr. Yablonka owns over 2,000 units of Brainstorm Cell Therapeutics stock worth over $2,112 and over the last 10 years he sold BCLI stock worth over $0. In addition, he makes $44,402 as Executive Vice President, Chief Business Officer, and Director at Brainstorm Cell Therapeutics.
Uri has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of BCLI stock worth $7,960 on 23 August 2017.
The largest trade he's ever made was buying 2,000 units of Brainstorm Cell Therapeutics stock on 23 August 2017 worth over $7,960. On average, Uri trades about 154 units every 0 days since 2014. As of 23 August 2017 he still owns at least 7,543 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Mr. Yablonka stock trades at the bottom of the page.
Uri Yablonka serves as Executive Vice President, Chief Business Officer, Director of the Company. Mr. Yablonka served since December 2010 as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. He also served since January 2011 as Vice President, Business Development at ACC International Holdings Ltd. (Holdings). Holdings is also an affiliate of ACCBT Corp. Prior to serving with Holdings, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. From 2008 to January 2011, Mr. Yablonka was Senior Partner at PM-PR Media Consulting Ltd., where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. His experience in business consulting and development and media experience are expected to be valuable to the Company in its current stage of growth and beyond, and his governmental experience can provide valuable insight into issues faced by companies in regulated industries such as ours. Yablonka to serve as a director of the Company.
As the Executive Vice President, Chief Business Officer, and Director of Brainstorm Cell Therapeutics, the total compensation of Uri Yablonka at Brainstorm Cell Therapeutics is $44,402. There are 8 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.
Uri Yablonka is 43, he's been the Executive Vice President, Chief Business Officer, and Director of Brainstorm Cell Therapeutics since 2017. There are 17 older and 1 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
Uri's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, and International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: